SpaceX Goes Public at $135 a Share. Is It a Buy at That Price?

SpaceX is set to IPO at $135 per share with an implied valuation near $2 trillion, but only about 5% of the company will be floated to the public. The stock would trade at 92x trailing 12-month sales, far above the S&P 500's 3.7x and the Nasdaq-100's 6.7x average price-to-sales ratios, which makes the article's takeaway cautious for retail investors. More than 20% of IPO shares are earmarked for retail, but the piece argues valuation and ongoing losses make the offering look expensive.

Analysis

The key market issue is not whether the IPO clears at the headline valuation, but whether the float is large enough to absorb incremental demand without forcing a post-deal air pocket. A ~5% public slice with a retail-heavy allocation is structurally supportive for day-one pricing, yet it also creates a reflexive setup: once the marginal buyer is exhausted, liquidity is thin and price discovery can become violent. That tends to favor underwriters, insiders, and platform brokers in the first phase, while late retail flow often becomes the exit liquidity after the first lockup-adjacent scare.

The more important second-order effect is competitive capital allocation. A 92x sales print resets the benchmark for private-market growth assets and will likely pressure late-stage venture investors to mark up adjacent aerospace, defense-tech, and AI infrastructure names even if their fundamentals are weaker. That said, the comparison set is dangerous: if this deal trades poorly, it will likely compress multiples across the long-duration growth cohort rather than just punish the issuer, because public investors will reprice scarce-growth narratives against more normal enterprise software and semiconductor comps.

The real catalyst path is months, not days. Near term, the stock can stay disconnected from fundamentals as scarcity and prestige dominate; the risk window starts when lockups approach and when the market begins to ask whether revenue growth can reaccelerate enough to justify continued multiple expansion. Any sign of margin dilution from public-company costs or slower top-line growth would matter disproportionately because the valuation leaves almost no room for execution error.

Contrarian view: the consensus mistake is treating this as a pure momentum/celebrity trade when it is actually a liquidity and positioning event. The better read is that the IPO may mark a local top in private-market enthusiasm for mega-capital-intensive growth stories, while benefiting incumbent public peers with cleaner cash conversion and lower supply overhang. If retail participation is front-loaded, the best risk/reward may be to fade the IPO after the opening imbalance rather than attempt to own it into the first lockup window.

Key Decisions for Investors

• Do not chase the IPO on day 1; wait 2-6 weeks for liquidity to normalize and for post-deal supply to reveal itself. Risk/reward is poor at the open if the float is absorbed by momentum buyers.
• Use weakness in NVDA and INTC only if the market starts treating the deal as a broad growth-comps reset; otherwise stay neutral. The more attractive trade is a relative-value long in profitable semis versus any unprofitable long-duration growth basket that gets re-rated by this IPO.
• If the stock trades 15-25% above issue price in the first week, consider a defined-risk short via call spreads or put spreads 1-3 months out. The thesis is that scarcity-driven gains can fade once initial retail demand is satisfied.
• Watch NFLX as an indirect beneficiary of retail attention and speculative capital rotation; if the IPO becomes a momentum magnet, high-beta public winners can get a transient multiple bid. This is a tactical 1-4 week trade only, not a fundamental endorsement.